Who is on it, and how far along Every drug ChEMBL records acting on EDNRA, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved5 Bosentan Bosentan SponsorJohnson & Johnson ModalitySmall molecule ActionAntagonist Open trials13 Ambrisentan Ambrisentan SponsorGilead Sciences ModalitySmall molecule ActionAntagonist Open trials9 Macitentan Macitentan SponsorJohnson & Johnson ModalitySmall molecule ActionAntagonist Open trials9 Aprocitentan Aprocitentan SponsorIdorsia ModalitySmall molecule ActionAntagonist Open trials1 Sitaxentan Sitaxentan SponsorPfizer ModalitySmall molecule ActionAntagonist Open trials1
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Endothelin receptor, ET-A/ET-B antagonist. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea Macitentan — Not yet recruiting Janssen Korea, Ltd., Korea Oct 22, 2026 Endothelin Role In COronary Microcirculation Bosentan Not applicable Active, not recruiting Liverpool University Hospitals NHS Foundation Trust Jun 26, 2026 A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension Aprocitentan Phase 3 Not yet recruiting CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Jun 9, 2026 Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive Angina Macitentan Early phase 1 Recruiting China-Japan Friendship Hospital Feb 6, 2026 COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities Ambrisentan Phase 3 Recruiting Assistance Publique - Hôpitaux de Paris Nov 24, 2025 Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Macitentan Phase 4 Recruiting Gachon University Gil Medical Center Aug 28, 2025 Nefecon and Ambrisentan in IgA Nephropathy Ambrisentan Phase 4 Recruiting The First Hospital of Jilin University Jun 22, 2025 The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension Ambrisentan, Bosentan — Recruiting University of Sao Paulo General Hospital Jun 10, 2025 Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension Ambrisentan Not applicable Not yet recruiting Nanjing First Hospital, Nanjing Medical University May 23, 2025 Comparison of Sequential to Initial Combination Therapy in PAH Ambrisentan Not applicable Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine May 13, 2025 Bosentan in the Treatment of Giant Cell Arteritis Bosentan Phase 2 Not yet recruiting Assistance Publique - Hôpitaux de Paris May 4, 2025 Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) Bosentan Phase 2 Recruiting University of Edinburgh Mar 20, 2025 Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC) Macitentan Early phase 1 Recruiting China-Japan Friendship Hospital Feb 6, 2025 Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study Macitentan — Recruiting Qianfoshan Hospital Dec 31, 2024 Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm Bosentan Phase 2 / Phase 3 Enrolling by invitation Radboud University Medical Center May 29, 2024 Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients Ambrisentan, Bosentan, Macitentan Phase 4 Recruiting AOP Orphan Pharmaceuticals AG Mar 19, 2024 Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome Ambrisentan Phase 2 Active, not recruiting Noorik Biopharmaceuticals AG Feb 13, 2024 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Macitentan Phase 3 Recruiting Actelion Jan 5, 2022 Endothelin-1 Receptor Blockade in Resistant Hypertension Bosentan Phase 2 Recruiting University Hospital, Rouen May 14, 2020 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) Bosentan — Recruiting Duke University Feb 20, 2020 Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Ambrisentan, Macitentan Phase 3 Active, not recruiting Actelion Feb 18, 2020 COMPERA / COMPERA-KIDS Sitaxentan — Recruiting Technische Universität Dresden May 4, 2011
Show all 22Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096678 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets